While pharma peers stumble, AbbVie defeated the patent cliff RSS CTA

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Investing.com — For years, the loss of exclusivity on Humira was treated as the moment the maker of the best-selling drug in history would hit an insurmountable wall. Wall Street warned of a multi-year earnings decline, prompting conservative investors to exit. Instead, AbbVie (NYSE:ABBV) has gained 16.8% since InvestingPro’s ProPicks AI models added the stock on August 1, including a 6.0% advance over the past month while the broader market retreated.

That divergence highlights where pharmaceutical capital is seeking safety. While peers like Pfizer (NYSE:PFE) navigate post-pandemic vaccine revenue drops and Bristol-Myers Squibb (NYSE:BMY) contends with near-term patent expirations, AbbVie delivered what healthcare investors rarely see during a major patent cliff: commercial replacements that fully absorb the revenue decline before the legacy franchise fades.

Recognizing when underlying pipeline execution outpaces market skepticism is what InvestingPro’s ProPicks AI models look for. The system maintains AbbVie in both the Beat the S&P 500 and Healthcare Heroes strategies. In Healthcare Heroes’ active November portfolio, AbbVie is paired with a focused group of resilient healthcare operators—including a commercial HIV and oncology therapeutics leader, an essential specialty healthcare turnaround operator, and a precision laboratory instrumentation supplier.

Replacing the best-selling drug in history

Third-quarter operating results showed how rapidly the commercial transition has progressed. AbbVie reported adjusted earnings per share of $3.82 against consensus expectations of $3.74, on total revenue of $17.4 billion, representing 10.5% operational sales growth. Even as global Humira sales dropped another 30.6% to $683 million, management raised full-year guidance, projecting adjusted EPS between $13.95 and $13.99 on revenue of approximately $67.8 billion.

The heavy lifting came from next-generation immunology. Skyrizi revenue grew 22.9% year-over-year to nearly $5.8 billion in the quarter, while Rinvoq advanced 24.3% to $2.7 billion. Management now guides full-year sales for the pair to $21.8 billion and $10.3 billion, respectively. Crucially, Skyrizi continues to capture roughly half of all new patient starts across psoriasis and inflammatory bowel disease, establishing a multi-year commercial moat.

Neuroscience has emerged as a durable secondary growth driver. Segment revenue rose 19.5% year-over-year to nearly $3.4 billion, supported by expanding adoption of Vraylar and Botox Therapeutic. Management lifted full-year neuroscience revenue guidance to $13 billion, with nine commercial therapies across the broader portfolio posting double-digit sales growth during the quarter.

Cash flow that funds the pipeline and shareholder returns

Operational execution continues to translate into substantial cash conversion. AbbVie generated approximately $14 billion in operating cash flow over the first nine months of 2026, self-funding strategic bolt-on acquisitions such as Apogee Therapeutics while supporting a 5.2% dividend hike to $1.82 per quarter. Counting its legacy years within Abbott Laboratories, the company has increased its dividend payout for 52 consecutive years, offering an attractive 2.5% yield.

Valuation multiples reflect an improving earnings trajectory. While trailing earnings appear elevated at 49.5 times, the stock trades at roughly 21.0 times forward earnings estimates with a PEG ratio of 0.15. Consensus analyst projections compiled on InvestingPro model EPS expanding from $14.04 this year to $16.25 in 2027. The median analyst price target sits at $306.42, indicating room for multiple expansion from recent trading levels near $291.31.

Product concentration remains the principal long-term risk. Skyrizi and Rinvoq accounted for nearly 49% of third-quarter net revenue, and Skyrizi’s initial U.S. patent protections begin expiring in 2033. Investors can review detailed immunology adoption curves, neuroscience revenue durability, and dividend payout coverage inside the AbbVie Pro Research Report.

Looking beyond pharmaceutical patent cycles

AbbVie demonstrates how commercial execution can neutralize a generational patent expiration. By replacing Humira’s declining sales with high-margin immunology and neuroscience revenue years ahead of schedule, the company has preserved free cash flow and dividend growth without taking on excessive balance-sheet risk.

Identifying that durability before broad market sentiment normalizes is the objective of ProPicks AI. Rather than avoiding pharmaceutical patent cycles out of caution, the Healthcare Heroes strategy systematically allocates capital into proven cash generators across commercial therapeutics, medical technology, and clinical diagnostics.

For investors seeking high-conviction ideas in the active November portfolios, full access to all ProPicks AI strategies costs just $9 a month.

The author holds no position in the stocks mentioned. Data and financial metrics as of November 9, 2026.